Robert W. Baird Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price objective lowered by equities research analysts at Robert W. Baird from $277.00 to $268.00 in a note issued to investors on Tuesday. The brokerage currently has an “overweight” rating on the conglomerate’s stock. Robert W. Baird’s price objective indicates a potential upside of 7.91% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. KeyCorp increased their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Citigroup decreased their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. UBS Group dropped their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $285.81.

Danaher Stock Down 0.9 %

Shares of DHR stock traded down $2.24 on Tuesday, reaching $248.35. 2,393,338 shares of the stock were exchanged, compared to its average volume of 2,872,787. Danaher has a twelve month low of $225.42 and a twelve month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $179.38 billion, a price-to-earnings ratio of 47.41, a PEG ratio of 4.43 and a beta of 0.83. The business’s 50 day moving average price is $235.75 and its 200 day moving average price is $253.65.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Coronation Fund Managers Ltd. boosted its stake in shares of Danaher by 29.9% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after purchasing an additional 1,470 shares during the last quarter. Ascent Group LLC boosted its holdings in shares of Danaher by 30.2% in the 2nd quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after purchasing an additional 512 shares during the last quarter. Quarry LP increased its holdings in shares of Danaher by 250.6% during the 2nd quarter. Quarry LP now owns 298 shares of the conglomerate’s stock worth $74,000 after buying an additional 213 shares during the last quarter. Regal Investment Advisors LLC raised its holdings in shares of Danaher by 1.9% in the 2nd quarter. Regal Investment Advisors LLC now owns 8,581 shares of the conglomerate’s stock worth $2,144,000 after purchasing an additional 157 shares during the period. Finally, B. Riley Wealth Advisors Inc. increased its position in Danaher by 5.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 11,035 shares of the conglomerate’s stock worth $2,760,000 after purchasing an additional 527 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.